ESPR - NASDAQ

Esperion Therapeutics, Inc.

ESPR·NASDAQ

$3.14

+0.32%

HealthcareBiotechnology

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$652.83M

EPS-0.1100

P/E Ratio-28.55

Earnings Date08/04/2026

465.89M

Assets

36%

3Y+88.0%

5Y+32.0%

10Y+90.0%

767.85M

Total Liabilities

3Y+34.0%

5Y+71.0%

10Y+4523.0%

-301.96M

Total Equity

-22%

3Y-7.0%

5Y+214.0%

10Y-232.0%

Esperion Therapeutics, Inc. Funding & Solvency Profile

ESPR · NASDAQ

Current Assets

Cash & Cash Equivalents167.85M

Net Receivables140.19M

Inventory105.12M

Other Current Assets-245.31M

Total Current Assets168 M

Non-Current Assets

Property, Plant & Equipment3.26M

Goodwill & Intangible Assets56.00K

Long-Term Investments0.00

Other Non-Current Assets-123.13M

Total Non-Current Assets-119873000

Total Assets

465.89M

Financial Health Analysis

Current Ratio

0.56x

Warning: Liquidity concerns. Current assets may not be sufficient to cover short-term obligations.

Working Capital

-132958000

Negative working capital indicates short-term liabilities exceed short-term assets—potential liquidity stress.

Asset Composition

36% Current

Capital-intensive business with significant long-term investments in property, equipment, or intangibles.

Esperion Therapeutics, Inc. Balance Sheet

ESPR • NASDAQ

Esperion Therapeutics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2002	Dec 2001	Dec 2000	Dec 1999
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	167.9M	144.8M	82.2M	124.8M	208.9M	305M	166.1M	37M	34.5M	38.2M	77.3M	85M	56.5M	6.5M	1.6M	40.5M	70.3M	70.2M	5.9M
Short-Term Investments	0.0	0.0	0.0	42.1M	50.4M	0.0	34.7M	0.0	0.0	0.0	0.0	0.0	3.5M	0.0	0.0	4.4M	0.0	0.0	0.0
Cash & Short-Term Investments	167.9M	144.8M	82.2M	166.9M	259.3M	305M	200.8M	37M	34.5M	38.2M	77.3M	85M	60.1M	6.5M	1.6M	44.9M	70.3M	70.2M	5.9M
Net Receivables	140.2M	80.1M	48.5M	33.7M	22.9M	12.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accounts Receivables	140.2M	80.1M	48.5M	33.7M	22.9M	12.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Inventory	105.1M	94.5M	65.6M	35.2M	34.4M	16.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	586K	193K	1M	1.1M	12.4M	10M	6.6M	3.7M	2M	2.1M	858K	558K	367.2K	92.8K	410K	1M	0.0	0.0
Other Current Assets	-245.3M	18M	4.5M	9.9M	11.2M	0.0	928K	0.0	0.0	0.0	0.0	0.0	361.5K	0.0	200.1K	0.0	0.0	1.1M	139K
Total Current Assets	167.9M	338M	201.1M	246.7M	329M	345.9M	211.7M	142.6M	203.9M	213.6M	214.4M	106.8M	60.6M	7.1M	1.9M	45.3M	71.3M	71.3M	6M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	3.3M	5.8M	4.7M	1.2M	2.6M	7.3M	2.7M	520K	435K	674K	807K	780K	80.8K	120.2K	251.5K	3M	3.3M	2.5M	2M
Goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.1M	3.1M	0.0	0.0
Intangible Assets	56K	56K	56K	0.0	0.0	56K	56K	56K	56K	56K	56K	56K	55.7K	53.8K	53.8K	0.0	0.0	3.5M	0.0
Goodwill & Intangible Assets	56K	56K	56K	56K	56K	56K	56K	56K	56K	56K	56K	56K	55.7K	53.8K	53.8K	3.1M	3.1M	3.5M	0.0
Long-Term Investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	99.3M	239.2M	204.3M	215.2M	56.5M	17.5M	0.0	0.0	0.0	0.0	0.0	0.0
Tax Assets	417.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	-123.1M	0.0	0.0	0.0	50M	0.0	0.0	-99.1M	-165.7M	-173.4M	-134.9M	-20.8M	0.0	-174K	10.4K	35K	633K	534K	0.0
Total Non-Current Assets	298M	5.8M	4.7M	1.3M	52.6M	7.4M	2.7M	819K	73.9M	31.6M	81.2M	36.6M	17.7M	174K	315.7K	6.1M	7.1M	6.5M	2M
Total Assets	465.9M	343.8M	205.8M	247.9M	381.6M	353.3M	214.4M	143.5M	277.8M	245.2M	295.6M	143.3M	78.3M	7.3M	2.2M	51.4M	78.3M	77.9M	8M
LIABILITIES
CURRENT LIABILITIES
Total Payables	65.1M	51.7M	31.7M	23M	17.6M	52M	28.9M	44.9M	20.4M	4.6M	707K	2M	2.2M	489K	694.4K	1.7M	2.9M	3.9M	1.4M
Accounts Payable	65.1M	51.7M	31.7M	23M	17.6M	52M	28.9M	44.9M	20.4M	4.6M	707K	2M	2.2M	476.3K	691.2K	1.7M	2.9M	3.9M	1.4M
Other Payables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.7K	3.2K	0.0	0.0	0.0	0.0
Accrued Expenses	0.0	68.4M	13.5M	56.3M	39.9M	22.7M	26.8M	17.6M	735K	9.3M	3.3M	2.8M	2M	60.7K	408.5K	0.0	0.0	0.0	0.0
Short Term Debt	89.7M	102.2M	34.8M	0.0	0.0	0.0	0.0	0.0	1M	1.7M	1.6M	638K	0.0	15.2M	0.0	1.1M	863K	697K	495K
Capital Lease Obligations (Current)	0.0	2.7M	1.6M	384K	1.4M	2.6M	454K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	0.0	0.0	0.0	0.0	0.0	0.0	37K	44K	38K	40K	37K	107K	94.6K	12.7K	3.2K	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	8.5M	25.4M	3.5M	5.7M	1.7M	2.2M	0.0	38K	40K	37K	107K	0.0	1.2M	0.0	0.0	0.0	0.0	0.0
Other Current Liabilities	146M	12.7M	49.2M	9.1M	8.8M	15.2M	7.8M	1.9M	11M	0.0	0.0	0.0	-509.0	1.4M	236.4K	2.2M	2.6M	2.5M	980.4K
Total Current Liabilities	300.8M	246.2M	156.2M	92.3M	73.4M	94.1M	66.1M	64.3M	33.1M	15.6M	5.6M	5.5M	4.2M	17.2M	1.3M	4.9M	6.4M	7.2M	2.9M
NON-CURRENT LIABILITIES
Long Term Debt	457.6M	483.7M	501.5M	259.9M	258.3M	179.4M	0.0	0.0	0.0	1M	2.7M	4.3M	0.0	7.5M	6.9M	7.7M	5.5M	3M	2.3M
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	634K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	8.7M	0.0	0.0	218.8M	245.7M	172.5M	127.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-7.7M	-5.5M	-3M	-219.0
Total Non-Current Liabilities	467M	486.3M	504.6M	479.4M	505.2M	355.3M	128.4M	0.0	0.0	1M	2.7M	4.3M	0.0	7.5M	6.9M	7.7M	5.5M	3M	2.3M
Capital Lease Obligations	653K	5.3M	4.6M	1M	1.9M	6M	1.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	767.9M	732.5M	660.8M	571.7M	578.5M	449.4M	194.5M	64.3M	33.1M	16.6M	8.3M	9.8M	4.2M	24.7M	8.2M	12.7M	11.8M	10.2M	5.2M
SHAREHOLDERS' EQUITY
Treasury Stock	-55M	-55M	-55M	-55M	-55M	-55M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	78.3B	24M	24M	0.0	0.0	0.0	0.0
Common Stock	245K	196K	118K	75K	61K	26K	27K	27K	26K	23K	23K	20K	15.4K	346.0	308.0	29K	29K	26K	1.9K
Additional Paid-In Capital	1.4B	1.3B	1.1B	1.1B	964.4M	797.7M	715.2M	677.5M	641.8M	458M	441.9M	238M	142.1M	610K	201.2K	133.4M	133.1M	110.7M	16.5M
Retained Earnings	-1.6B	-1.6B	-1.5B	-1.3B	-1.1B	-838.8M	-695.3M	-598.1M	-396.3M	-229.2M	-154.2M	-104.4M	-68.1M	-42M	-30.2M	-94M	-65.3M	-40.4M	-12.8M
Accumulated Other Comprehensive Income/Loss	0.0	0.0	0.0	-2K	-31K	0.0	23K	-319K	-845K	-172K	-482K	-59K	-3K	-1.2M	-1M	-3.7M	-2.4M	-1.3M	-471.6K
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-78.3B	1.2M	0.0	-651K	-1.4M	-2.6M	-841K
Total Stockholders' Equity	-302M	-388.7M	-455M	-323.8M	-196.9M	-96.1M	20M	-598.1M	244.7M	228.6M	287.3M	133.6M	74.1M	-17.4M	-6.1M	38.7M	66.5M	67.7M	2.8M
Total Equity	-302M	-388.7M	-455M	-323.8M	-196.9M	-96.1M	20M	-598.1M	244.7M	228.6M	287.3M	133.6M	74.1M	-17.4M	-6.1M	38.7M	66.5M	67.7M	2.8M
SUMMARY
Total Liabilities & Equity	465.9M	343.8M	205.8M	247.9M	381.6M	353.3M	214.4M	-533.8M	277.8M	245.2M	295.6M	143.3M	78.3M	7.3M	2.2M	51.4M	78.3M	77.9M	8M
Total Investments	0.0	0.0	0.0	42.1M	50.4M	0.0	34.7M	99.3M	239.2M	204.3M	215.2M	56.5M	21.1M	0.0	0.0	4.4M	0.0	0.0	0.0
Total Debt	548M	591.2M	540.9M	260.9M	260.2M	185.4M	1.6M	0.0	1M	2.7M	4.3M	4.9M	0.0	22.8M	6.9M	8.8M	6.3M	3.7M	2.8M
Net Debt	380.1M	446.5M	458.7M	136.2M	51.3M	-119.6M	-164.6M	-37M	-33.4M	-35.4M	-73M	-80.1M	-56.5M	16.3M	5.3M	-31.7M	-63.9M	-66.5M	-3.1M
Shares Outstanding	197,530,548	197,530,548	197,530,548	197,530,548	197,530,548	197,530,548	197,530,548	197,530,548	197,530,548	197,530,548	197,530,548	197,530,548	197,530,548	197,530,548	197,530,548	197,530,548	197,530,548	197,530,548	197,530,548

SEC Filings

ESPR - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	June 01, 2026	May 28, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 08, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 01, 2026	May 01, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 16, 2026	April 16, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 02, 2026	April 02, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 10, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 10, 2026	March 10, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 03, 2026	March 02, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 12, 2026	January 11, 2026	2026	View Filing
10-Q 10-Q 2025 Q3 Q3	November 06, 2025	September 30, 2025	2025	View Filing

Showing 1 to 10 of 249 filings

Related Guides

Blog Categories

Continue your ESPR research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.